CurrentUnitedHealthcarePolicy 2026T0661E

Respiratory Pathogen Nucleic Acid Detection Testing – Commercial and Individual Exchange Medical Policy

UnitedHealthcare Commercial and Individual Exchange medical policy governing coverage rationale and applicable coding for respiratory pathogen nucleic acid detection testing, with specific stance on multiplex panels of six or more targets in outpatient settings and referenced CPT/HCPCS/PLA codes.

Policy Summary

PayerUnitedHealthcare

PolicyRespiratory Pathogen Nucleic Acid Detection Testing – Commercial and Individual Exchange Medical Policy

Policy CodePolicy 2026T0661E

Change TypeRevised supporting information and referencesadded related policy link

Effective DateApr 1, 2026

Next Review Date

Key ActionWhen deciding coverage, reference the member specific benefit plan document and applicable federal or state mandates; member plan governs in event of conflict.

SourceLink

POLICY UPDATE CHANGES

Updated Description of Services, Clinical Evidence, and References sections to reflect the most current information.

>=6Panel target count threshold for outpatient not medically necessary

9,414Individuals in Liu et al. mNGS meta-analysis

85Studies in Liu et al. mNGS meta-analysis

360Participants in Meltzer et al. RCT (urgent care)

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Summary

UnitedHealthcare Commercial and Individual Exchange medical policy on respiratory pathogen nucleic acid detection testing addresses molecular assays such as reverse transcription–polymerase chain reaction (RT-PCR) and metagenomic next-generation sequencing (mNGS) for detecting nucleic acids of respiratory pathogens. The policy notes that detection of microbial nucleic acid by these methods does not confirm viable virus or ongoing replication, and clinical utility varies by clinical setting and patient population.

The scope covers UnitedHealthcare Commercial and Individual Exchange plans and specifically addresses multiplex respiratory pathogen panels. The policy position specifies that multiplex panels with ≥ 6 targets in outpatient settings are considered unproven and not medically necessary due to insufficient evidence of clinical benefit.

Policy summary

Effective dateApril 1, 2026

Last reviewApril 1, 2026

Policy number2026T0661E

Coverage stanceRespiratory pathogen panel testing of six or more targets in an outpatient setting is unproven and not medically necessary

Number of panel targets (threshold)>= 6 targets (in outpatient setting considered unproven / not medically necessary)

Policy conclusion: Insufficient evidence to support respiratory pathogen panel testing of six or more targets in outpatient settings; considered unproven and not medically necessary, with the outpatient use specifically not supported by current evidence.

Medical-Necessity Criteria

Coverage Rationale

Policy position:

Respiratory pathogen panel testing of six or more targets in an outpatient setting is unproven and not medically necessary due to insufficient evidence of efficacy for all indications.>= 6 targets (in outpatient setting considered unproven / not medically necessary)

Coding

Proprietary/Lab Developed / PLA and CPT/HCPCS codes referencedmixed

0115U	Respiratory infectious agent detection by nucleic acid (DNA and RNA), 18 viral types and subtypes and 2 bacterial targets, amplified probe technique, including multiplex reverse transcription for RNA targets, each analyte reported as detected or not detected.
0202U	Infectious disease (bacterial or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 22 targets including SARS-CoV-2, qualitative RT-PCR, nasopharyngeal swab, each pathogen reported as detected or not detected.
0223U	Infectious disease (bacterial or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 22 targets including SARS-CoV-2, qualitative RT-PCR, nasopharyngeal swab, each pathogen reported as detected or not detected.
0225U	Infectious disease (bacterial or viral respiratory tract infection) pathogen-specific DNA and RNA, 21 targets, including SARS-CoV-2, amplified probe technique, including multiplex reverse transcription for RNA targets, each analyte reported as detected or not detected.
0556U	Infectious disease (bacterial or viral respiratory tract infection), pathogen-specific DNA and RNA by real-time PCR, 12 targets, nasopharyngeal or oropharyngeal swab, including multiplex reverse transcription for RNA targets, each analyte reported as detected or not detected.
0563U	Infectious disease (bacterial and/or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 11 viral targets and 4 bacterial targets, qualitative RT-PCR, upper respiratory specimen, each pathogen reported as positive or negative.
0564U	Infectious disease (bacterial and/or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 10 viral targets and 4 bacterial targets, qualitative RT-PCR, upper respiratory specimen, each pathogen reported as positive or negative.
87632	Infectious agent detection by nucleic acid (DNA or RNA); respiratory virus, includes multiplex reverse transcription and multiplex amplified probe technique, multiple types or subtypes, 6-11 targets.
87633	Infectious agent detection by nucleic acid (DNA or RNA); respiratory virus, includes multiplex reverse transcription and multiplex amplified probe technique, multiple types or subtypes, 12-25 targets.

Provider Actions

Documentation Required

Reference member specific benefit plan

When deciding coverage, reference the member specific benefit plan document and applicable federal or state mandates; member plan governs in event of conflict.

Documentation Required

Use clinical judgment and diagnostic stewardship

Interpret multiplex panel results in clinical context due to issues like prolonged shedding, coinfections, variable accuracy by target, and limited evidence of improved outcomes in outpatients; consider testing only for patients at high risk or hospitalized per guideline recommendations.

Prolonged shedding can complicate interpretation of positive results.
Multiplex panels may detect coinfections or multiple organisms; results require clinical correlation.
Accuracy and performance vary by target and specimen type; negative results do not always rule out infection.
Limited evidence that multiplex panels improve outpatient outcomes; consider testing primarily for high-risk or hospitalized patients per guidelines.

Background & Evidence

Molecular assays include multiplex RT-PCR assays that detect predefined viral and/or bacterial nucleic acid targets in respiratory specimens and metagenomic next-generation sequencing (mNGS) that enables comprehensive detection of genetic material from all organisms in a sample. The policy highlights that while multiplex panels can identify coinfections and multiple organisms and mNGS may be promising—particularly when conventional tests fail—there are important detection limitations: nucleic acid detection does not confirm viable organisms or ongoing replication, panel performance varies by target and specimen type, some targets have limited sensitivity or cross-reactivity, and semiquantitative results can complicate interpretation. For outpatients, the fixed composition of larger multiplex panels often includes pathogens unlikely to require simultaneous testing, results may reflect prolonged shedding or colonization, and available evidence does not demonstrate improved individual outcomes with routine multiplex testing in otherwise stable outpatient populations; therefore diagnostic stewardship and selective testing for high-risk or hospitalized patients are recommended.

Evidence metrics

Unsupported block type: metric

Definitions

Unsupported block type: definition

Revision History

04/01/2026revisionLatest

Updated Description of Services, Clinical Evidence, and References sections to reflect the most current information.

04/01/2026related_policy_reference_addedLatest

Added reference link to the Reimbursement Policy titled Laboratory Services Policy, Professional; archived previous policy version 2026T0661D.